摘要
目的评价经动脉化疗栓塞（TACE）联合索拉非尼治疗大肝癌的疗效与安全性。方法回顾分析中山大学附属第一医院2008年7月至2012年6月收治的79例大肝癌（直径〉10cm）患者的临床资料，分为3组，24例行TACE联合索拉非尼治疗（T＋S组），35例行单纯TACE治疗（T组），20例单纯服用索拉非尼治疗（s组）。结果T＋S组、T组、S组中位生存期（MST）分别为15、10、5个月（P=0．000）；3组的中位肿瘤进展时间（TTP）分别为6．0、3．0、2．5个月（P=0．000），T＋S组与S组的索拉非尼相关不良反应的发生率差异无统计学意义（P〉0．05），主要为手足皮肤反应、腹泻和脱发，无4级以上的严重不良反应。T＋S组与T组的介入治疗相关并发症发生率差异无统计学意义（P〉0．05），主要为轻度的黄疸、腹水和腹股沟血肿。结论TACE联合索拉非尼治疗大肝癌安全性和耐受性良好，可有效控制肿瘤进展，延长患者生存期。
Objective To evaluate the efficacy and safety of combined transarterial ehemoembolization with sorafenib in patients with large hepatocellular carcinoma. Methods 79 patients with large HCC （larger than 10 cm in diameter）were enrolled from July 2008 to June 2012 for this retrospective study. 24 patients undertaken TACE combined with sorafenib as T ＋ S group. 35 patients undertaken TACE alone as T group, and other 20 patients treated with sorafenib alone as S group. Results The median survival time was 15 months in T ＋S group, 10 months in T group, and 5 months in S group, respectively （P = 0. 000 ）. The median time of tumor progress was 6 months, 3 months and 2. 5 months, respectively（ P = 0. 000）. The most common adverse events related to sorafenib in group T ＋ S group and S group alone were hand foot skin reaction, diarrhea and alopeeia. The incidence rate of adverse events related to sorafenib was no significant difference between two groups. There was no 4 or more grade adverse event occurred in each group. The most common complications related to interventional treatment in group T ＋ S group and T group alone were mild jaundice, ascites, inguinal region hematoma. The incidence rate of complications related to interventional treatment was no significant difference between two groups. Conclusion The combination of TACE and sorafenib in patients with large HCC is well tolerated and safe, which is available to delay tumor progression and prolong survival.
出处
《中华医学杂志》
CAS
CSCD
北大核心
2013年第13期987-991,共5页
National Medical Journal of China
基金
国家自然科学基金（81171441）
教育部留学回国人员科研启动基金（20111139）
广东省科技计划项目（20118031800146）
关键词
癌
肝细胞
药物疗法
联合
栓塞
Carcinoma, hepatocellular
Drug therapy, combination
Embolism
